BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 37860184)

  • 1. Advance in integrating platinum-based chemotherapy with radiotherapy for locally advanced nasopharyngeal carcinoma.
    Zhu F; Wu Y; Wang H
    Front Oncol; 2023; 13():1259331. PubMed ID: 37860184
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in locally advanced nasopharyngeal carcinoma.
    Setakornnukul J; Thephamongkhol K
    BMC Cancer; 2018 Mar; 18(1):329. PubMed ID: 29587665
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Retrospective Analysis of Induction Chemotherapy plus Concurrent Chemoradiotherapy under Intensity-Modulated Radiotherapy Mode for Locally Advanced Nasopharyngeal Carcinoma.
    Liao K; Tao HY; Zhan ZJ; Qiu WZ; Zheng RH
    Oncol Res Treat; 2021; 44(11):602-612. PubMed ID: 34601467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Meta-Analysis on Induction Chemotherapy in Locally Advanced Nasopharyngeal Carcinoma.
    Mané M; Benkhaled S; Dragan T; Paesmans M; Beauvois S; Lalami Y; Szturz P; Gaye PM; Vermorken JB; Van Gestel D
    Oncologist; 2021 Jan; 26(1):e130-e141. PubMed ID: 32924198
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of lobaplatin combined with 5-fluorouracil as first-line induction chemotherapy followed by lobaplatin-radiotherapy in locally advanced nasopharyngeal carcinoma: preliminary results of a prospective phase II trial.
    Ke LR; Xia WX; Qiu WZ; Huang XJ; Yang J; Yu YH; Liang H; Liu GY; Ye YF; Xiang YQ; Guo X; Lv X
    BMC Cancer; 2017 Feb; 17(1):134. PubMed ID: 28202000
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of induction chemotherapy plus concurrent chemoradiotherapy and induction chemotherapy plus radiotherapy in locally advanced nasopharyngeal carcinoma.
    Wang Q; Xu G; Xia Y; Zuo J; Zeng G; Xue Z; Cao R; Xiong W; Li W
    Oral Oncol; 2020 Dec; 111():104925. PubMed ID: 32721816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparing the efficacy and safety of cisplatin and other platinum-based chemotherapies in locally advanced nasopharyngeal carcinoma: a systematic review and meta-analysis.
    Li Z; Li C; Yang D; Song J; Liu T; Zhou Z; Zhou L; Kang M
    BMC Cancer; 2022 Jun; 22(1):616. PubMed ID: 35668431
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD3+T-lymphocyte infiltration is an independent prognostic factor for advanced nasopharyngeal carcinoma.
    Al-Rajhi N; Soudy H; Ahmed SA; Elhassan T; Mohammed SF; Khoja HA; Ghebeh H
    BMC Cancer; 2020 Mar; 20(1):240. PubMed ID: 32199452
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I/II trial evaluating concurrent carbon-ion radiotherapy plus chemotherapy for salvage treatment of locally recurrent nasopharyngeal carcinoma.
    Kong L; Gao J; Hu J; Hu W; Guan X; Lu R; Lu JJ
    Chin J Cancer; 2016 Dec; 35(1):101. PubMed ID: 28007028
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of adjuvant chemotherapy on survival in patients with residual nasopharyngeal carcinoma after undergoing concurrent chemoradiotherapy.
    Yang S; Lin S; Fu Q; Cai B; Kong F; Huang G; Li F; Wang H
    PLoS One; 2015; 10(3):e0120019. PubMed ID: 25799566
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of therapeutic efficacy and toxicity of docetaxel, cisplatin, and fluorouracil (TPF)-based induction chemotherapy plus concurrent chemoradiotherapy and chemoradiotherapy alone in locally advanced nasopharyngeal carcinoma.
    Chen R; Lu Y; Zhang Y; He R; Tang F; Yuan W; Li Y; Zhang X
    Medicine (Baltimore); 2021 Oct; 100(42):e27475. PubMed ID: 34678878
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Experience of weekly cisplatin concurrent with intensity-modulated radiotherapy for locally advanced nasopharyngeal carcinoma patients with resistance to neoadjuvant chemotherapy.
    Chen C; Chen T; Huang C; Wang J; Fei Z
    Medicine (Baltimore); 2017 Nov; 96(44):e8434. PubMed ID: 29095283
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concurrent chemoradiotherapy plus anlotinib vs. concurrent chemoradiotherapy alone in locally advanced nasopharyngeal carcinoma: An interim analysis of a multicenter randomized controlled trial.
    Chen K; Xu G; Liang Y; Liang P; Gao W; Li Z; Liang W; Tao Z; Chen J; Hu X; Xu Y
    Oncol Lett; 2023 Sep; 26(3):392. PubMed ID: 37600344
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High expression of XPA confers poor prognosis for nasopharyngeal carcinoma patients treated with platinum-based chemoradiotherapy.
    Fu X; Hu J; Han HY; Hua YJ; Zhou L; Shuai WD; Du WY; Kuang CM; Chen S; Huang W; Liu RY
    Oncotarget; 2015 Sep; 6(29):28478-90. PubMed ID: 26156020
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-endemic locoregionally advanced nasopharyngeal carcinoma: long-term outcome after induction plus concurrent chemoradiotherapy in everyday clinical practice.
    Boscolo-Rizzo P; Tirelli G; Mantovani M; Baggio V; Lupato V; Spinato G; Gava A; Da Mosto MC
    Eur Arch Otorhinolaryngol; 2015 Nov; 272(11):3491-8. PubMed ID: 25367705
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of induction docetaxel, platinum, and fluorouracil chemotherapy in patients with stage III or IVA/B nasopharyngeal cancer treated with concurrent chemoradiation therapy: Final results of 2 parallel phase 2 clinical trials.
    Kong L; Zhang Y; Hu C; Guo Y; Lu JJ
    Cancer; 2017 Jun; 123(12):2258-2267. PubMed ID: 28192641
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Platinum-based concurrent chemotherapy remains the optimal regimen for nasopharyngeal carcinoma: a large institutional-based cohort study from an endemic area.
    Yu Y; Liang H; Lv X; Ke L; Qiu W; Huang X; Liu G; Li W; Guo X; Xiang Y; Xia W
    J Cancer Res Clin Oncol; 2018 Nov; 144(11):2231-2243. PubMed ID: 30109501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival benefit of adding docetaxel, cisplatin, and 5-fluorouracil induction chemotherapy to concurrent chemoradiotherapy for locally advanced nasopharyngeal carcinoma with nodal Stage N2-3.
    Kawahira M; Yokota T; Hamauchi S; Onozawa Y; Ogawa H; Onoe T; Kamijo T; Iida Y; Nishimura T; Onitsuka T; Yasui H
    Jpn J Clin Oncol; 2017 Aug; 47(8):705-712. PubMed ID: 28431119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction chemotherapy plus concomitant chemoradiotherapy in nasopharyngeal carcinoma: An updated network meta-analysis.
    Bongiovanni A; Vagheggini A; Fausti V; Mercatali L; Calpona S; Di Menna G; Miserocchi G; Ibrahim T
    Crit Rev Oncol Hematol; 2021 Apr; 160():103244. PubMed ID: 33582249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploratory Study of NPC-0501 Trial: Optimal Cisplatin Dose of Concurrent and Induction/Adjuvant Chemotherapy for Locoregionally Advanced Nasopharyngeal Carcinoma.
    Ng WT; Choi CW; But B; Ngan RKC; Tung S; Cheng AC; Kwong DLW; Lu TX; Chan ATC; Yiu H; Lee S; Wong F; Yuen KT; Chappell RJ; Lee AWM
    Clin Cancer Res; 2022 Jun; 28(12):2679-2689. PubMed ID: 35381064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.